Clinical Trial Update: Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the impact of obesity on the pharmacokinetics of imipenem-cilastatin/relebactam in ICU patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Illness
• Obesity

Drugs mentioned

• Imipenem/Cilastatin/Relebactam (imipenem/cilastatin/relebactam)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Obesity, Critical Illness | Phase 4 | Status: WITHDRAWN